Janssen Biotech Licenses Ex-Japan Rights to Astellas’ Oral JAK Inhibitor ASP015K
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 10 (Table of Contents)
Published: 17 Oct-2012
DOI: 10.3833/pdr.v2012.i10.1821 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to strengthen its autoimmune disease franchise, Johnson & Johnson’s Janssen Biotech has licensed worldwide rights, excluding Japan, to develop and commercialise Astellas Pharma’s ASP015K, a Janus kinase (JAK) inhibitor in Phase IIb development for moderate-to-severe rheumatoid arthritis (RA)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS